XSHG
603739
Market cap436mUSD
Jul 09, Last price
11.71CNY
1D
-1.18%
1Q
-21.78%
IPO
-50.96%
Name
Qingdao Vland Biotech Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Qingdao Vland Biotech Inc. specializes in the research, development, and production of enzymes, probiotics, animal vaccines, and veterinary health products. Its extensive product range features enzymes for animal feed, industrial uses, and food processing, along with various probiotics, such as aquaculture premixes, general health supplements, and both animal and plant-specific formulations. The company also provides a comprehensive array of animal vaccines and biological solutions, including both live and inactivated vaccines for poultry and swine, in addition to antibodies. Its offerings extend to poultry pharmaceuticals, covering antiparasitic, antiviral, and nutritional medications, alongside disinfectants. Furthermore, it supplies traditional Chinese veterinary remedies designed for aquatic species, poultry, and livestock, including laying hens. Vland Biotech's diverse clientele operates across numerous sectors, such as agriculture, animal husbandry, textile manufacturing, papermaking, household cleaning and detergents, food production, biofuel development, and environmental protection. This entity, established in 2005 and headquartered in Qingdao, China, operates as a subsidiary of Qingdao Kangdien Industrial Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||